Purpose: To evaluate the long-term outcome (up to 7 years) of presumed ocular tuberculosis (TB) when the therapeutic decision was based on WHO guidelines.
Methods: Twelve out of 654 new uveitic patients (1998-2004) presented with choroiditis and positive tuberculosis skin test (TST) (skin lesion diameter >15 mm). Therapy was administered according to WHO recommendations after ophthalmic and systemic investigation. The area size of ocular lesions at presentation and after therapy, measured on fluorescein and indocyanine green angiographies, was considered the primary outcome. Relapse of choroiditis was considered a secondary outcome. The T-SPOT TB test was performed when it became available.
Results: Visual acuity significantly improved after therapy (p=0.0357). The mean total surface of fluorescein lesions at entry was 44.8 ± 20.9 (arbitrary units) and decreased to 32.5 ± 16.9 after therapy (p=0.0165). The mean total surface of indocyanine green lesions at entry was 24.5 ± 13.3 and decreased to 10.8 ± 5.4 after therapy (p=0.0631). The T-SPOT TB revealed 2 false TST-positive results. The mean follow-up was 4.5 ± 1.5 years. Two relapses out of 10 confirmed ocular TB was observed after complete lesion healing, 2.5 years and 4.5 years after therapy, respectively.
Conclusions: A decrease of ocular lesion mean size and a mean improvement of VA were observed after antituberculous therapy. Our long-term follow-up of chorioretinal lesions demonstrated relapse of ocular tuberculosis in 10% of patients with confirmed ocular TB, despite complete initial retinal scarring.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5301/EJO.2011.8423 | DOI Listing |
BMC Ophthalmol
January 2025
Department of Tuberculosis, New District Branch of Northern Jiangsu People's Hospital of Jiangsu Province, Yangzhou, 225001, Jiangsu Province, China.
Background: This study aims to detect Mycobacterium tuberculosis complex (MTBC) DNA in intraocular fluid from clinically suspected tuberculous uveitis patients using multiplex polymerase chain reaction (PCR) and investigate the diagnostic utility of multiplex PCR for tuberculous uveitis.
Methods: Primers targeting three specific genes (MPB64, CYP141, and IS6110) within the MTBC genome were designed. Multiplex PCR was conducted using DNA from the H37Rv strain as well as DNA extracted from fluids of confirmed tuberculosis patients to assess primer specificity and method feasibility.
Zhonghua Yan Ke Za Zhi
January 2025
Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin300052, China.
Ocul Immunol Inflamm
December 2024
Beijing Ophthalmology & Visual Science Key Lab, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Purpose: Ocular tuberculosis (OTB), an extrapulmonary manifestation of tuberculosis (TB), significantly impacts vision acuity and presents challenges in diagnosis and treatment. With ongoing research efforts, new insights into its pathogenesis and treatment have emerged. This study employed bibliometric methods to investigate key research areas and emerging trends, aiming to provide a comprehensive overview of the field.
View Article and Find Full Text PDFJ Maxillofac Oral Surg
December 2024
Department of Oral & Maxillofacial Surgery, Army Dental Centre (Research & Referral), Cantt-10, Delhi, India.
Tuberculosis (TB) manifests in various forms, including extrapulmonary tuberculosis (EPTB), which poses diagnostic dilemmas due to its wide-ranging clinical presentations. When TB affects the bones of the hands and feet, it can present a diagnostic labyrinth for clinicians. In such cases, the differential diagnosis may include Jungling's bone disease, adding complexity to the diagnostic process.
View Article and Find Full Text PDFJ Curr Ophthalmol
October 2024
Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada.
Purpose: To describe the first reported instance of an acute chorioretinal inflammatory response to cabozantinib.
Methods: Case report.
Results: A 54-year-old Asian male presented with blurred vision 2 weeks following the commencement of cabozantinib for metastatic renal cell carcinoma.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!